Search PubMed⌕ Search

Biomedical subjects

D B Marin

Publications and source records attributed to D B Marin.

23 records · Page 2Linked to original sources
PubMed1989

Dementia with coexistent major depression.

Eleven percent (N = 25) of 232 dementia patients seen in an active geropsychiatry service also met criteria for major depression. Ten patients with dementia/depression were prospectively compared with 10 non-depressed demented and 33 nondemented depressed patients on pretreatment and posttreatment ratings of depression and cognition/memory. Seventy percent (N = 7) of the dementia/depression group and 73% (N = 24) of the depression-only group responded to antidepressant therapy. Signs and symptoms of depression complicating dementia were similar to depressive phenomena in the depression-only group. Depression with dementia appeared to lower performance on cognitive tests. Following treatment, although cognitive impairment remained in the demented range, test performance improved.

Aged↗
PubMed1989

Personality disorders: issues in assessment.

The multiaxial system adopted in DSM-III (American Psychiatric Association 1980) has fostered much research in the area of the assessment of personality disorders. This paper will address issues and controversies that have an impact on the assessment of personality. Topics to be discussed in this paper include (1) a review of and comparison between categorical and dimensional approaches to personality classification; (2) discussion of differing viewpoints regarding the most appropriate way to conceptualize Axis II diagnoses, with emphasis on their relationship with Axis I and II conditions; and (4) a review of between Axis I and II conditions; and (4) a review of different assessment instruments.

Humans↗
PubMedDate not supplied

Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.

Anti-inflammatory drugs may be useful in the treatment of Alzheimer disease (AD). In preparation for therapeutic trials, we conducted pilot feasibility studies of hydroxychloroquine alone and in combination with colchicine in subjects with AD. A total of 20 subjects with probable AD were treated with hydroxychloroquine 200 mg twice daily for 11 weeks, or hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks; subjects were monitored for adverse medical, cognitive, or behavioral effects. Neither regimen caused adverse effects on cognitive or behavioral assessment scores. There were no significant side effects in subjects receiving hydroxychloroquine alone; 2 subjects receiving the two drugs together experienced diarrhea. We conclude that these regimens of anti-inflammatory therapy are well tolerated in subjects with AD, indicating the feasibility of large-scale therapeutic trials of these agents.

Aged↗